This is a preview of subscription content, log in via an institution to check access.
Notes
The multi-component tablet, containing a statin, three BP-lowering drugs (atenolol, ramipril and hydrochlorothiazide at half doses), aspirin and folic acid, was designed to reduce CV events.
The study was partly supported by a grant from sanofi-aventis australia.
Reference
Zomer E, et al. Predicting the Impact of Polypill Use in a Metabolic Syndrome Population: An Effectiveness and Cost-Effectiveness Analysis. American Journal of Cardiovascular Drugs : 27 Mar 2013. Available from: URL: http://dx.doi.org/10.1007/s40256-013-0019-2
Rights and permissions
About this article
Cite this article
Polypill an option for metabolic syndrome?. PharmacoEcon Outcomes News 676, 7 (2013). https://doi.org/10.1007/s40274-013-0322-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0322-9